The FDA-cleared BioButton® wearables, algorithmic-based data analytics, and comprehensive in-hospital monitoring solution empower clinicians with unprecedented health status insights and personalized vital sign trends to effectively manage vulnerable transplant patients for potential signs of clinical deterioration
DENVER & SACRAMENTO, Calif.–(BUSINESS WIRE)–BioIntelliSense, a continuous health monitoring and clinical intelligence company, and California-based UC Davis Health announce the launch of a new in-hospital monitoring initiative for patients hospitalized for Bone Marrow Transplant and Hematology/Oncology services. The transformational program leverages the BioIntelliSense FDA-cleared BioButton® wearable devices, algorithmic-based data analytics, and clinical intelligence system to monitor for subtle changes in vital sign trends and signs of potential patient deterioration for actionable clinical decisions and proactive interventions.
“Our first priority is to provide the best care experience possible, which is even more critical when dealing with our most vulnerable patients, who are at risk for changes in condition,” said Christine Williams, interim chief nursing and patient care services officer at UC Davis Health. “With the BioButton device and timely insights, our clinical teams can explore new innovations and solutions for continuously monitoring a patient’s health status.”
Jason Adams, associate professor of Pulmonary, Critical Care, and Sleep Medicine and director of Data and Analytics Strategy with UC Davis Health Innovation Technology (IT), adds, “Identifying patients with meaningful signs of deterioration before the point of critical illness is the key to avoiding a potential health crisis and improving patient outcomes. Continuous patient monitoring with the BioButton wearable is allowing us to rethink what’s possible and to work on AI-driven solutions that may eventually anticipate bad outcomes and enable the shift to a more proactive model of care.”
The medical-grade BioButton device passively captures up to 1,440 sets of vital sign measurements per patient per day for monitoring of medical-surgical patients and potential adverse trends that may indicate post-procedure complications. The multi-parameter BioButton device, applied to the patient’s upper left chest, seamlessly and securely collects high-frequency heart rate at rest, respiratory rate at rest, and skin temperature trending, along with a broad range of physiologic biometrics. Clinically meaningful and statistically significant changes in vital signs allow for an intuitive display of contextual patient data and algorithmic-based notifications in the comprehensive BioIntelliSense clinical intelligence solution.
“It’s an honor to partner with such an esteemed and innovative healthcare leader as UC Davis Health to advance the next standard of patient care fueled by medical grade and scalable tech-enabled solutions,” said James Mault, MD, Founder and CEO of BioIntelliSense. “Smart care is the future of healthcare, and we are delivering on that promise with the introduction of this continuous care program at UC Davis Health.”
An award-winning academic medical center, UC Davis Health is a recognized leader in advancing digital transformation initiatives focused on equitable, accessible, and cost-effective patient care. The BioIntelliSense project has been led and driven by the cutting-edge UC Davis Health Digital CoLab and their commitment to identifying, evaluating, and implementing best-in-class technologies and programs.
“We are committed to deploying and scaling innovative technology that ensures all our patients receive the highest quality care available, no matter where they are – at home, in the hospital, or post-acute care,” said Ashish Atreja, CIO and chief digital health officer at UC Davis Health.
“We want to empower our clinical teams with the most advanced tools available, so they can effectively and efficiently personalize every patient’s care. Our strategic collaboration with BioIntelliSense is an important part of this mission. We want to continuously monitor vital signs and only interrupt a patient’s recovery time when the trending data suggests we need to proactively intervene, whether that patient is in the hospital or the comfort of their home,” said David Lubarsky, vice chancellor of human health sciences and CEO of UC Davis Health.
ABOUT BIOINTELLISENSE
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs and physiological biometrics through an effortless patient experience. The FDA-cleared BioButton® wearable device and end-to-end solution makes continuous monitoring reliable and scalable. Through the platform’s algorithmic-based analytics, clinicians have access to high-resolution patient trending and reporting from in-hospital to home.
ABOUT UC DAVIS HEALTH
UC Davis Health is improving lives and transforming healthcare by providing excellent patient care, conducting groundbreaking research, fostering innovative, interprofessional education, and creating dynamic, productive partnerships. UC Davis Health harnesses the power of an entire university’s nationally ranked resources and research to tackle the most pressing healthcare issues facing the world today. As the northern California region’s only academic health center, UC Davis Health is focused on discovering and sharing knowledge and providing the highest quality of care and serves as a hub of innovation that encompasses UC Davis Medical Center, UC Davis School of Medicine, The Betty Irene Moore School of Nursing at UC Davis, and UC Davis Medical Group.
Contacts
Media:
BioIntelliSense, Inc.
Eric Schudiske
UC Davis Health
Liam Connolly
